Experienced in Alpha Thalassemia

Dr. Richard P. Mansour

Hematology Oncology | Hematology | Oncology
Lsu Health Sciences Center Shreveport Faculty Group Practice
1541 Kings Hwy, 
Shreveport, LA 
 (1067.1 mi)
Accepting New Patients
Experienced in Alpha Thalassemia
Lsu Health Sciences Center Shreveport Faculty Group Practice
1541 Kings Hwy, 
Shreveport, LA 
 (1067.1 mi)
OverviewInsuranceLocationsClinical Research

Overview

Richard Mansour is a Hematologist Oncology specialist and a Hematologist in Shreveport, Louisiana. Dr. Mansour and is rated as an Experienced provider by MediFind in the treatment of Alpha Thalassemia. His top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mansour is currently accepting new patients.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Alpha Thalassemia.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in LA
Hospital Affiliations
Ochsner Lsu Health Shreveport
Ochsner Lsu Health Shreveport-St Mary Medical Cent
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  Humana

Locations

LSU HEALTH SCIENCES CENTER SHREVEPORT FACULTY GROUP PRACTICE
1541 Kings Hwy, Shreveport, LA 71103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: November 29, 2024
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
A Phase II, Multicenter, Randomized, Open Label Two Arm Study Evaluating the Effect of Crizanlizumab + Standard of Care and Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)
Enrollment Status: Completed
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drug: Crizanlizuamb
Study Phase: Phase 2
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
A Prospective Phase II, Open-Label, Single-arm, Multicenter, Study to Assess Efficacy and Safety of SEG101 (Crizanlizumab), in Sickle Cell Disease Patients With Priapism (SPARTAN)
Enrollment Status: Completed
Publish Date: April 04, 2024
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
View 3 Less Clinical Trials

17 Total Publications

Real-world Data of Leukopenia Evaluation as Seen in a Community Academic Center.
Real-world Data of Leukopenia Evaluation as Seen in a Community Academic Center.
Journal: Journal of community hospital internal medicine perspectives
Published: July 19, 2023
Similar Doctors
Experienced in Alpha Thalassemia
Dr. Joyce E. Feagin
Hematology Oncology | Hematology | Oncology
Experienced in Alpha Thalassemia
Dr. Joyce E. Feagin
Hematology Oncology | Hematology | Oncology

Wk Hematology Oncology Associates

2600 Kings Hwy, Suite 340, 
Shreveport, LA 
 (1.0 mi)
318-212-8620
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joyce Feagin is a Hematologist Oncology specialist and a Hematologist in Shreveport, Louisiana. Dr. Feagin and is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia. Her top areas of expertise are Inflammatory Breast Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast. Dr. Feagin is currently accepting new patients.

Experienced in Alpha Thalassemia
Dr. Samip R. Master
Hematology Oncology | Hematology | Oncology
Experienced in Alpha Thalassemia
Dr. Samip R. Master
Hematology Oncology | Hematology | Oncology

Wk Hematology Oncology Associates

2600 Kings Hwy, Suite 340, 
Shreveport, LA 
 (1.0 mi)
318-212-8620
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Samip Master is a Hematologist Oncology specialist and a Hematologist in Shreveport, Louisiana. Dr. Master and is rated as a Distinguished provider by MediFind in the treatment of Alpha Thalassemia. His top areas of expertise are Sickle Cell Disease, Acute Myeloid Leukemia (AML), Paget Disease of the Breast, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Master is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile